Abbott out-licenses asthma agent
Abbott licenses rights for controlled-release and I.V. formulations of asthma agent zileuton to Critical Therapeutics. Abbott markets an immediate-release version of zileuton, Zyflo Filmtab. Critical Therapeutics will handle all regulatory, manufacturing and marketing responsibility and will make milestone and royalty payments to Abbott...
You may also be interested in...
Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.
Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.
Dutch foot-care specialists TheOTCLab launches what it claims to be the world's first fungal nail plaster.